Vitreous Opacity Vitrectomy (VOV): Safest Possible Removal of "Floaters"

Clin Ophthalmol. 2022 Jun 1:16:1653-1663. doi: 10.2147/OPTH.S361557. eCollection 2022.

Abstract

Purpose: Primary opacities that develop in the aging vitreous, commonly termed "floaters," were once considered merely a nuisance, not justifying any risk of surgical removal. However, vitreoretinal specialists are increasingly recognizing that extensive symptomatic vitreous opacities (SVO) that substantially interfere with activities that critically depend on vision (daily visual activities, DVA), constituting degenerative vitreous syndrome (DVS, see http://floaterstories.com), warrant removal albeit with minimal risk - but no description of how to reduce vitrectomy risks to least possible has been forthcoming. We here describe such a method.

Patients and methods: The safest possible removal of extensive SVO as described herein was attained by an operation specifically designed for DVS treatment (vitreous opacity vitrectomy, VOV), rather than as only a means of achieving subsequent retinal surgery in the same procedure, as is usually the case. We retrospectively reviewed the outcomes of 100 consecutive VOV operations (in 81 patients, average age 66) performed with ultra-high speed, 27-gauge vitrectomy probes.

Results: All eyes rapidly achieved continuously clear vision, and no eye developed a clinically significant complication during a year of follow-up. Three small, existent retinal breaks were discovered prior to peripheral vitrectomy and one apparently iatrogenic retinal tear was found at VOV completion, when each was treated. In the eyes that were not pseudophakic, postoperative nuclear sclerosis progression was successfully managed by subsequent cataract extraction.

Conclusion: The goals of VOV for DVS are to safely restore continuously clear vision by performing tractionless vitreous removal with respect to the retina and to reduce the lifetime risk of retinal detachment, both by such vitreous removal and by microscopic examination of the peripheral retina under anesthesia (MEPRUA), guiding appropriate prophylactic retinopexy. The otherwise healthy DVS eyes so treated warrant this specific form of vitrectomy, continually focused on achieving least possible risk, to maintain an acceptable risk/benefit ratio.

Keywords: daily visual activities; degenerative vitreous syndrome; floaters; retinal tear; symptomatic vitreous opacities; vitrectomy; vitreous opacity vitrectomy.

Grants and funding

Support for this research was provided by the Helen Keller Foundation for Research and Education, through grants by the Hanna Charitable Trust of Birmingham, Alabama and by the Kent Companies, Midland, Texas.